Brookline Capital Management Predicts ADIL Q1 Earnings

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) – Research analysts at Brookline Capital Management issued their Q1 2025 earnings per share (EPS) estimates for Adial Pharmaceuticals in a note issued to investors on Tuesday, March 4th. Brookline Capital Management analyst K. Dolliver expects that the company will earn ($0.62) per share for the quarter. The consensus estimate for Adial Pharmaceuticals’ current full-year earnings is ($1.53) per share. Brookline Capital Management also issued estimates for Adial Pharmaceuticals’ Q2 2025 earnings at ($0.83) EPS, Q3 2025 earnings at ($1.25) EPS, Q4 2025 earnings at ($1.46) EPS and FY2025 earnings at ($2.70) EPS.

Other equities analysts also recently issued reports about the stock. RODMAN&RENSHAW raised shares of Adial Pharmaceuticals to a “strong-buy” rating in a report on Thursday, November 14th. Rodman & Renshaw assumed coverage on Adial Pharmaceuticals in a report on Thursday, November 14th. They issued a “buy” rating and a $8.00 target price on the stock.

Adial Pharmaceuticals Trading Down 2.6 %

Shares of NASDAQ:ADIL opened at $0.75 on Friday. The business’s fifty day moving average price is $0.89 and its two-hundred day moving average price is $0.98. Adial Pharmaceuticals has a fifty-two week low of $0.70 and a fifty-two week high of $3.10.

Adial Pharmaceuticals (NASDAQ:ADIL) last released its quarterly earnings data on Tuesday, March 4th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.23.

Institutional Trading of Adial Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Citadel Advisors LLC lifted its holdings in Adial Pharmaceuticals by 63.8% during the 4th quarter. Citadel Advisors LLC now owns 54,508 shares of the company’s stock worth $55,000 after buying an additional 21,238 shares in the last quarter. Renaissance Technologies LLC bought a new stake in shares of Adial Pharmaceuticals during the fourth quarter worth $48,000. Finally, Geode Capital Management LLC lifted its stake in shares of Adial Pharmaceuticals by 36.0% during the fourth quarter. Geode Capital Management LLC now owns 61,847 shares of the company’s stock valued at $62,000 after acquiring an additional 16,381 shares during the period. 16.41% of the stock is owned by institutional investors.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.